Immunotherapy has revolutionized colon cancer treatment. Immune checkpoint inhibitors
(ICIs) have shown clinical benefits for colon cancer patients, especially those with high …

Colorectal cancer (CRC) affects 1 in 23 males and 1 in 25 females, making it the third most
common cancer. With roughly 608000 deaths worldwide, CRC accounts for 8% of all cancer …

The long-term remissions induced by immune-checkpoint inhibitors (ICIs) in many types of
cancers have opened up the possibility of a broader use of immunotherapy in less …

The clinical success of immunotherapy has revolutionized the treatment of cancer patients,
bringing renewed attention to tumor-infiltrating lymphocytes (TILs) of various cancer types …

Background Although cancer immunotherapy is one of the most effective advanced-stage
cancer therapies, no clinically approved cancer immunotherapies currently exist for …

Immune checkpoints (ICs) have pivotal roles in regulating immune responses. The inhibitory
ICs in the tumor microenvironment (TME) have been implicated in the immune evasion of …

TIGIT is a lymphocyte surface receptor, which is mainly expressed on the surface of CD8+ T
cells. The role of TIGIT in colorectal cancer and its expression pattern in colorectal cancer …

Simple Summary The human body consists of trillions of cells and several million of them die
daily. These natural processes which determine the fate of a cell in the human body can be …

Immune checkpoint inhibition (ICI) therapies have reshaped the therapeutic landscape in
lung cancer management, providing first-time improvements in patient response, prognosis …

The rapid increase in collateral omics and phenotypic data has enabled data-driven studies
for the fast discovery of cancer targets and biomarkers. Thus, it is necessary to develop …